Adamis Pharmaceuticals Corporation announced that in studies conducted at Galveston National Laboratory (GNL), University of Texas Medical Branch (UTMB) at Galveston, hamsters challenged with high levels of the Omicron variant of the SARS-CoV-2 virus resulted in significant decrease of inflammation in the lungs of animals treated with Tempol compared to controls.
Two months after receiving a gene-edited pig heart, David Bennett Sr. passed away at the age of 57 years.
The discovery of the Omicron variant in white-tailed deer in New York raised concerns that the species – numbering 30 million in the United States – could become hosts of a new coronavirus strain, a lead researcher said on February 8.
Merck & Co. and Ridgeback Biotherapeutics announced they have supplied about 3.1 million courses of their antiviral drug against COVID-19, molnupiravir, to the U.S. government. In other news, a study funded by the National Institutes of Health found that vaccination against COVID-19 not only protects pregnant women against the disease but their babies as well.
A new study by the American Stroke Association found that the risk of stroke in adults with COVID-19 between the ages of 65 to 74 was highest the first three days after diagnosis. Additionally, investigators at the National Institutes of Allergy and Infectious Diseases’ Vaccine Research Center ran tests on primates and found that updating COVID-19 vaccines to focus on the Omicron variant may not provide much benefit.
A U.S. man with terminal heart disease was implanted with a genetically modified pig heart in a first-of-its-kind surgery, and three days later the patient is doing well, his doctors reported on January 10.
Surgeons from NYU Langone Health hit a major milestone in transplantation science after successfully attaching a pig’s kidney to a human patient and watching it work for several hours.
The mission of new startup Colossal, which has raised $15 million to date, is to genetically reengineer a cold-resistant elephant with all the core biological traits of the extinct woolly mammoth.
Monoclonal antibodies are playing a key therapeutic role in the treatment of some Covid-19 patients, but new research suggests that nanobodies derived from llamas could provide an alternative to monoclonal antibodies through a more effective delivery method—inhalation.
Llama antibodies could soon be playing a role in the global fight against Covid-19, if clinical trials being conducted by a Belgian biomedical start-up live up to their early promise.